Request availability and a quotation for your required quantity and destination.
| Product | Ivermectin 24 mg - Ivermectin Tablets |
|---|---|
| Categories | Ivermectin, Ivermectin & Fenbendazole |
| Pack Size | 200 Tablets, 300 Tablets, 100 Tablets |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Catalogue categories: Ivermectin · Ivermectin & Fenbendazole
Dosage form: Oral tablet
Listed strength: 24 mg — verify manufacturer’s pack and regulatory authorization
This listing describes ivermectin 24 mg tablets. Ivermectin is an antiparasitic medicine used for specific confirmed parasitic infections. The unusually high listed tablet strength requires independent verification and does not establish a recommended dose, product approval, or suitability for personal use.
U.S. oral ivermectin labeling includes intestinal strongyloidiasis and onchocerciasis. Clinical guidelines may describe additional indications, such as scabies, depending on the setting. Treatment selection must follow an accurate diagnosis and an appropriate prescriber-selected regimen.
A labelled 24 mg tablet is not interchangeable with lower-strength ivermectin products without professional assessment. Do not determine a treatment course from a catalogue strength or use unverified multi-drug protocols. Verify origin, actual composition, and applicable local registration before clinical use.
Ivermectin can cause dizziness, nausea, rash and other adverse effects; serious neurologic reactions have been reported. Individuals with relevant infection exposures, pregnancy, neurological conditions or other medication use need professional assessment. Animal ivermectin products must never be used as substitutes.
Oral ivermectin is approved in the United States for intestinal strongyloidiasis and onchocerciasis; other uses differ by jurisdiction and guidelines.
A 24 mg or 40 mg tablet strength is not itself a standard dosing recommendation. Dosing depends on diagnosis, weight and clinical judgment.
Oral ivermectin is used for scabies in some guidelines, but this is not an FDA-approved oral indication; a qualified clinician decides suitability.
The FDA has not authorized or approved ivermectin to prevent or treat COVID-19.
There is no established clinical evidence supporting ivermectin as an approved cancer treatment.
No. Animal formulations differ and can cause serious harm in people.
Nausea, dizziness, rash and other reactions are possible. Serious neurologic events have been reported.
Interactions and medical history should be reviewed with the prescriber, including blood-thinning therapy.
Pregnancy and breastfeeding require individual clinical risk assessment.
Different parasitic infections require different treatments, and inaccurate diagnosis may delay needed care.
Cureiva provides educational information and handles lawful medicine enquiries subject to manufacturer authenticity, prescription rules and destination-country requirements. No clinician sign-off is claimed.